Trial Profile
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Opaganib (Primary)
- Indications Diffuse large B cell lymphoma; Kaposi's sarcoma
- Focus Adverse reactions
- Sponsors Apogee Biotechnology Corporation; RedHill Biopharma
- 05 Dec 2017 Planned initiation date changed from 1 Apr 2015 to 1 Jul 2014.
- 05 Dec 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 25 Apr 2017 New indication 'kaposi sarcoma' has been added and changes in title, endpoints, patient inclusion criteria also.